SWK Holdings focuses on pharmaceutical development, manufacturing and intellectual property licensing business. Co.'s operations comprise two reportable segments: Finance Receivables, which provides customized financing solutions to a range of life science companies, institutions and inventors, and focuses on commercial-stage products and related intellectual property through royalty purchases and financings, as well as through commercialized products; and Pharmaceutical Development, in which through its subsidiary, Enteris BioPharma, Inc., provides formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. The SWKH YTD return is shown above.
The YTD Return on the SWKH YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether SWKH YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SWKH YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|